Hepatitis E Virus Protease Inhibits the Activity of Eukaryotic Initiation Factor 2-Alpha Kinase 4 and Promotes Virus Survival.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
29 06 2023
Historique:
medline: 3 7 2023
pubmed: 18 5 2023
entrez: 18 5 2023
Statut: ppublish

Résumé

Multiple mechanisms exist in a cell to cope with stress. Four independent stress-sensing kinases constitute the integrated stress response machinery of the mammalian cell, and they sense the stress signals and act by phosphorylating the eukaryotic initiation factor 2α (eIF2α) to arrest cellular translation. Eukaryotic initiation factor 2 alpha kinase 4 (eIF2AK4) is one of the four kinases and is activated under conditions of amino acid starvation, UV radiation, or RNA virus infection, resulting in shutdown of global translation. An earlier study in our laboratory constructed the protein interaction network of the hepatitis E virus (HEV) and identified eIF2AK4 as a host interaction partner of the genotype 1 (g1) HEV protease (PCP). Here, we report that PCP's association with the eIF2AK4 results in inhibition of self-association and concomitant loss of kinase activity of eIF2AK4. Site-directed mutagenesis of the 53rd phenylalanine residue of PCP abolishes its interaction with the eIF2AK4. Further, a genetically engineered HEV-expressing F53A mutant PCP shows poor replication efficiency. Collectively, these data identify an additional property of the g1-HEV PCP protein, through which it helps the virus in antagonizing eIF2AK4-mediated phosphorylation of the eIF2α, thus contributing to uninterrupted synthesis of viral proteins in the infected cells.

Identifiants

pubmed: 37199644
doi: 10.1128/jvi.00347-23
pmc: PMC10308950
doi:

Substances chimiques

Endopeptidases EC 3.4.-
Eukaryotic Initiation Factor-2 0
Viral Proteins 0
EIF2AK4 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
Amino Acids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0034723

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Biol Chem. 1996 May 31;271(22):13202-7
pubmed: 8662715
Front Microbiol. 2022 Feb 24;13:828636
pubmed: 35283856
J Virol. 2006 Dec;80(23):11817-26
pubmed: 16987971
J Virol. 2001 Jul;75(14):6249-55
pubmed: 11413290
J Virol. 2019 Sep 12;93(19):
pubmed: 31315997
J Gen Virol. 2013 Apr;94(Pt 4):807-816
pubmed: 23255617
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2438-43
pubmed: 21262830
Front Microbiol. 2020 Apr 15;11:656
pubmed: 32351484
Sci Rep. 2016 Apr 26;6:25133
pubmed: 27113483
J Virol. 2016 Sep 12;90(19):8478-86
pubmed: 27440879
Int J Gynaecol Obstet. 2004 Jun;85(3):240-4
pubmed: 15145258
BMC Biochem. 2012 May 16;13:7
pubmed: 22590978
PLoS Pathog. 2016 Apr 01;12(4):e1005521
pubmed: 27035822
J Virol. 2004 May;78(9):4838-46
pubmed: 15078965
Virol J. 2006 May 26;3:38
pubmed: 16725054
EMBO J. 2006 Apr 19;25(8):1730-40
pubmed: 16601681
Sci Rep. 2017 Jul 19;7(1):5816
pubmed: 28725041
PLoS One. 2012;7(10):e47272
pubmed: 23110064
J Virol. 2000 Jul;74(13):6203-6
pubmed: 10846107
J Biol Chem. 2006 Mar 24;281(12):8135-42
pubmed: 16407257
Science. 2020 Apr 24;368(6489):
pubmed: 32327570
World J Gastroenterol. 2017 Jan 28;23(4):590-602
pubmed: 28216965
J Gen Virol. 2011 Dec;92(Pt 12):2838-2848
pubmed: 21880841
PLoS Pathog. 2016 Feb 02;12(2):e1005437
pubmed: 26837067
Ann Intern Med. 2007 Jul 3;147(1):28-33
pubmed: 17606958
J Virol. 2012 May;86(10):5697-707
pubmed: 22398290
Virus Res. 2013 Dec 26;178(2):553-6
pubmed: 23978667
mSystems. 2018 Jan 23;3(1):
pubmed: 29404423
J Virol. 2017 Oct 13;91(21):
pubmed: 28814517
Front Microbiol. 2020 Feb 06;11:141
pubmed: 32117160
Virol J. 2011 May 20;8:245
pubmed: 21595991
PLoS Genet. 2015 Feb 19;11(2):e1004991
pubmed: 25695491
J Biol Chem. 2003 Jun 6;278(23):20457-60
pubmed: 12676950
Virology. 2023 Jan;578:128-140
pubmed: 36527931
J Virol. 2017 Feb 14;91(5):
pubmed: 27974558
J Gen Virol. 2011 Sep;92(Pt 9):2088-2092
pubmed: 21653754
J Virol. 2011 Oct;85(19):10031-40
pubmed: 21775444
Mol Cell Biol. 1998 May;18(5):2697-711
pubmed: 9566889
J Virol. 2010 Sep;84(18):9637-41
pubmed: 20592074
J Virol. 2006 Jun;80(12):5919-26
pubmed: 16731930
J Virol. 1997 Apr;71(4):2583-90
pubmed: 9060609
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1147-1152
pubmed: 28096411
Biochim Biophys Acta. 2014 Sep;1843(9):1948-68
pubmed: 24732012
J Virol. 2010 Apr;84(7):3595-602
pubmed: 20071563
J Virol. 2007 Apr;81(7):3377-90
pubmed: 17229688
Biomed Res Int. 2018 Jan 9;2018:5769201
pubmed: 29546064
Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8259-63
pubmed: 1518855
Viruses. 2016 Aug 15;8(8):
pubmed: 27537905
J Virol. 2007 Apr;81(7):3339-45
pubmed: 17229684
J Virol. 2009 Jan;83(1):384-95
pubmed: 18945785
Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):96-110
pubmed: 29162935
Sci Rep. 2016 Jun 08;6:27597
pubmed: 27270888
J Virol. 2014 Oct;88(20):11924-32
pubmed: 25100852

Auteurs

Amit Kumar (A)

Virology Laboratory, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.

Chandru Subramani (C)

Virology Laboratory, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.

Shivani Raj (S)

University School of Biotechnology, Guru Gobind Singh Indraprastha University, New Delhi, India.

C T Ranjith-Kumar (CT)

University School of Biotechnology, Guru Gobind Singh Indraprastha University, New Delhi, India.

Milan Surjit (M)

Virology Laboratory, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH